Hematopoiesis is characterized by incessant production of a variety of cell types from hematopoietic stem cells (HSC). During this process, HSC generate progenitor populations with progressively reduced lineage potentials. We have directly shown the existence of such progenitor populations by prospective purification on a fluorescence-activated cell sorter. These include the earliest lymphoid-committed progenitors (common lymphoid progenitor; CLP), the earliest myeloid-committed progenitors (common myeloid progenitors: CMP), the granulocyte/monocyte progenitor (GMP), and the megakaryocyte/ erythrocyte progenitor (MEP). Using these prospectively-purified progenitor populations, we will evaluate whether cytokines play instructive as well as permissive roles in lineage determination. In this proposal, we will focus on three important branch points of hematopoiesis; 1) CLP vs. CMP development from HSC, 2) MEP vs. GMP development from CMP, and 3) eosinophil, mast cell, and neutrophil development from GMP. First, the physiological roles of cytokines in hematopoiesis will be evaluated at the progenitor level. We will analyze coexpression of various cytokine receptors in progenitors by using single cell RT-PCR systems. Then we will evaluate the effect of cytokine depletion on differentiation potentials of each progenitor subset. We will evaluate biological characteristics of progenitors isolated from mice deficient for myeloid and lymphoid-related cytokines. Next, we will evaluate whether ectopic IL-7R signals can reprogram myeloid progenitors to transdifferentiate into lymphoid lineages, whether ectopic GM-CSFR or G-CSFR signals can transdifferentiate lymphoid progenitors into myeloid lineage, and whether transgenic IL-5R signals can instruct GMP to differentiate into eosinophils. This system will also be used to evaluate the effect of oncogenic tyrosine kinase fusions on lineage determination, whose signals considerably resemble those of cytokines. We will retrovirally transduce BCR-ABL and TEL-PTK fusions into progenitors to test whether lineage conversion occurs after the transduction. We hope that this study will help elucidate the mechanisms of lineage commitment in normal and malignant hematopoiesis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Program Projects (P01)
Project #
2P01DK050654-06
Application #
6583506
Study Section
Special Emphasis Panel (ZDK1)
Project Start
2002-08-01
Project End
2007-07-31
Budget Start
Budget End
Support Year
6
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02115
Jiang, Jingrui; Griffin, James D (2010) Wnt/?-catenin Pathway Modulates the Sensitivity of the Mutant FLT3 Receptor Kinase Inhibitors in a GSK-3? Dependent Manner. Genes Cancer 1:164-76
Weisberg, E; Ray, A; Barrett, R et al. (2010) Smac mimetics: implications for enhancement of targeted therapies in leukemia. Leukemia 24:2100-9
Weisberg, Ellen; Roesel, Johannes; Furet, Pascal et al. (2010) Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison. Genes Cancer 1:1021-32
Weisberg, Ellen; Choi, Hwan Geun; Ray, Arghya et al. (2010) Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. Blood 115:4206-16
Weisberg, E; Deng, X; Choi, H G et al. (2010) Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML. Leukemia 24:1375-8
Weisberg, Ellen; Choi, Hwan Geun; Barrett, Rosemary et al. (2010) Discovery and characterization of novel mutant FLT3 kinase inhibitors. Mol Cancer Ther 9:2468-77
Moldovan, George-Lucian; Madhavan, Mahesh V; Mirchandani, Kanchan D et al. (2010) DNA polymerase POLN participates in cross-link repair and homologous recombination. Mol Cell Biol 30:1088-96
Weisberg, E; Sattler, M; Ray, A et al. (2010) Drug resistance in mutant FLT3-positive AML. Oncogene 29:5120-34
Kim, Jung Min; Parmar, Kalindi; Huang, Min et al. (2009) Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype. Dev Cell 16:314-20
Mercher, Thomas; Raffel, Glen D; Moore, Sandra A et al. (2009) The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. J Clin Invest 119:852-64

Showing the most recent 10 out of 111 publications